Sign Up Today and Learn More About Areteia Therapeutics Stock
Invest in or calculate the value of your shares in Areteia Therapeutics or other pre-IPO companies through EquityZen's platform.
Areteia Therapeutics Stock (ARET)
Areteia Therapeutics is a biotechnology company committed to putting asthma patients in better control of their disease.
About Areteia Therapeutics Stock
Founded
2022
Headquarters
Bernardsville, NJ, US
Industries
Science and Engineering, Health Care, Biotechnology
Areteia Therapeutics Press Mentions
Stay in the know about the latest news on Areteia Therapeutics
Areteia Therapeutics Announces Appointments of Donald J. Hayden, Jr. and Ian F. Smith to Its Board of Directors
biospace • Mar 27, 2025
Areteia Therapeutics Announces Appointments of Donald J. Hayden, Jr. and Ian F. Smith to Its Board of Directors
businesswire • Mar 26, 2025
Biz: Midtown Raleigh tower fills retail space
bizjournals • Mar 14, 2025
Use of dexpramipexole for the treatment of moderate to severe asthma
patents • Feb 08, 2025
Compositions and methods for treating conditions related to elevated levels of …
patents • Feb 08, 2025
Areteia Therapeutics Management
Leadership team at Areteia Therapeutics
Board Member
Adam Koppel
Board Member
Paul L Berns
Join now and verify your accreditation status to gain access to:
- Areteia Therapeutics Current Valuation
- Areteia Therapeutics Stock Price
- Areteia Therapeutics Management
- Available deals in Areteia Therapeutics and all other companies with relevant Deal Offering documents
- EquityZen's proprietary data and insights, which may include
- Areteia Therapeutics Cap Table and Funding History by Share Class and Liquidity Preferences
- Areteia Therapeutics Revenue and Financials
- Areteia Therapeutics Highlights
- Areteia Therapeutics Business Model
- Areteia Therapeutics Risk Factors
- Areteia Therapeutics Research Report from SACRA Research
Trading Areteia Therapeutics Stock
How to invest in Areteia Therapeutics stock?
Accredited investors can buy pre-IPO stock in companies like Areteia Therapeutics through EquityZen funds. These investments are made available by existing Areteia Therapeutics shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process here.
How to sell Areteia Therapeutics stock?
Shareholders can sell their Areteia Therapeutics stock through EquityZen's private company marketplace. EquityZen's network includes over 360K accredited investors interested in buying private company stock. Learn more about the easy and guided Shareholder process here.
If I invest, how do I exit my investment?
There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. More information on Express Deals can be found here and exit information can be found here.
Why choose EquityZen?
Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 46K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."
